2019
DOI: 10.1021/acsmedchemlett.9b00065
|View full text |Cite
|
Sign up to set email alerts
|

Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage

Abstract: Necroptosis has been implicated in a variety of disease states, and RIPK3 is one of the kinases identified to play a critical role in this signaling pathway. In an effort to identify RIPK3 kinase inhibitors with a novel profile, mechanistic studies were incorporated at the hit triage stage. Utilization of these assays enabled identification of a Type II DFG-out inhibitor for RIPK3, which was confirmed by protein crystallography. Structure-based drug design on the inhibitors targeting this previously unreported… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
32
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(33 citation statements)
references
References 28 publications
(60 reference statements)
1
32
0
Order By: Relevance
“…These include autophosphorylation sites, which mark its activation towards necroptosis, as well as several phosphosites by accessory kinases, which were proposed to inhibit RIPK1's kinase activity. [205]; 4M69 [105]; 4BTF [30]).…”
Section: Post-translational Modifications Of Ripk1mentioning
confidence: 99%
“…These include autophosphorylation sites, which mark its activation towards necroptosis, as well as several phosphosites by accessory kinases, which were proposed to inhibit RIPK1's kinase activity. [205]; 4M69 [105]; 4BTF [30]).…”
Section: Post-translational Modifications Of Ripk1mentioning
confidence: 99%
“…To date, several small-molecule compounds (Li et al, 2014;Fauster et al, 2015;Martens et al, 2017Martens et al, , 2020Park et al, 2018;Pan et al, 2019;Hart et al, 2020) have been developed to inhibit RIPK3 activity, providing an impressive toolbox for the investigation of the role of RIPK3 in diverse tissues. These inhibitors of RIPK3 can be divided into three types: ATP mimetic inhibitors targeting the active ATP-binding site in the kinases located between two catalytic domain lobes (type I), targeting the inactive states (type II), and unclassified inhibitors (Muller et al, 2015;Martens et al, 2020; Table 1).…”
Section: Implications For Anti-fibrotic Therapymentioning
confidence: 99%
“…Four different Ripk3 inhibitors (GSK872, GSK840, GSK843, and RIPK3-IN-1) [ 43 , 44 ] were purchased from MedChemExpress, USA. The concentrations of these inhibitors used were listed in Table 1 .…”
Section: Methodsmentioning
confidence: 99%